Integral DiagnosticsASX:IDX -0.50%73 FCF Margin % is 2.03% as of Dec. 2025, which is 68% below its 10-year median of 6.42. GuruFocus rates ASX:IDX with a GF Score™ of 73/100 and a GF Value™ of A$2.78 (Modestly Undervalued). The stock has 9 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Integral Diagnostics ranks better than 59.8% on this metric.
The historical rank and industry rank for Integral Diagnostics's FCF Margin % or its related term are showing as below:
ASX:IDX'
s FCF Margin % Range Over the Past 10 Years
Min: 2.23 Med: 6.42 Max: 14.13
Current: 3.48
During the past 10 years, the highest FCF Margin % of Integral Diagnostics was 14.13%. The lowest was 2.23%. And the median was 6.42%.
ASX:IDX's FCF Margin % is ranked better than 59.8% of 204
companies
in the Medical Diagnostics & Research industry
Industry Median: -1.845
vs ASX:IDX: 3.48
Integral Diagnostics FCF Margin % Related Terms
Integral Diagnostics FCF Margin % Historical Data
* Premium members only.
The historical data trend for Integral Diagnostics's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ASX:IDX vs TMO, DHR, IDXX: FCF Margin % Comparison
For the Diagnostics & Research subindustry, Integral Diagnostics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Integral Diagnostics FCF Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Integral Diagnostics's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Integral Diagnostics's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Integral Diagnostics (ASX:IDX) has a FCF Margin % of 2.03% as of Dec. 2025. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Integral Diagnostics and its competitors. This is 68% below median its historical median of 6.42. Over the past decade, Integral Diagnostics' FCF Margin % has ranged from 2.23 to 14.13. According to the industry distribution chart, Integral Diagnostics ranks #82 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 40.2%.
Is Integral Diagnostics' FCF Margin % too high?
Integral Diagnostics' current FCF Margin % of 2.03% is 68% below median its 10-year median of 6.42. Over the past 10 years, this metric has ranged from a low of 2.23 to a high of 14.13. Based on the distribution chart, Integral Diagnostics ranks #82 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Integral Diagnostics has a GF Score™ of 73/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Integral Diagnostics' FCF Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Integral Diagnostics ranks #82 out of 204 companies for FCF Margin %. This puts Integral Diagnostics in the upper half of its industry. Historically, Integral Diagnostics' own FCF Margin % has ranged from 2.23 to 14.13 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Medical Diagnostics & Research company?
A good FCF Margin % depends on the Medical Diagnostics & Research industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Integral Diagnostics and its competitors. Integral Diagnostics's current FCF Margin % is 2.03%, which is 68% below median its own 10-year median of 6.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Integral Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, Integral Diagnostics (ASX:IDX) is currently considered Modestly Undervalued. The stock's GF Value™ is A$2.78, compared to a current price of A$2.00 — trading 28.1% below its estimated fair value. The current FCF Margin % is 2.03%, which is 68% below median its 10-year median of 6.42. Integral Diagnostics' overall GF Score™ is 73/100 with 9 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Integral Diagnostics (ASX:IDX), the current FCF Margin % is 2.03% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Integral Diagnostics (ASX:IDX) Overvalued in 2026?
Based on GuruFocus' analysis, Integral Diagnostics stock appears to be undervalued.
The current stock price of A$2.00 is trading 28.1% below its estimated GF Value™ of A$2.78.
GuruFocus considers Integral Diagnostics to be Modestly Undervalued.
Key valuation signals for ASX:IDX:
FCF Margin %: 2.03% (68% below median its 10-year median of 6.42)
GF Value™: A$2.78 vs. price of A$2.00 (28.1% below fair value)
No single metric tells the full story. See the ASX:IDX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Integral Diagnostics is a major Australian diagnostic imaging provider. In Australia, imaging revenues are almost entirely earned via the public health Medicare system. Integral typically earns approximately 90% of group revenue from diagnostic imaging in Australia and the remainder from diagnostic imaging in Auckland, New Zealand. In Australia, Integral services regional areas in Queensland, Victoria, New South Wales, and Western Australia.
73GF Score
Get the complete analysis for ASX:IDX
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:IDX has been successfully added to your 
